Viromed Medical AG Advances in Cold Plasma Technology with ViroCAP® med Approval

Viromed Medical AG has announced the successful completion of the regulatory approval process for its ViroCAP® med device. The device is now classified as a Class IIa medical device under the EU Medical Device Regulation. This classification certifies its safety and performance, enabling its market introduction across Europe.

ViroCAP® med utilizes cold atmospheric plasma technology for wound treatment, effectively inactivating viruses, bacteria, and spores. This innovation targets the reduction of germs and has been positively received at the European Wound Congress 2026 held in Bremen.

The management at Viromed anticipates strong demand for ViroCAP® med in clinical settings. The company highlights its benefits for both patients and physicians and expects a rapid uptake in hospitals and clinics.

The European Wound Management Association congress served as a platform for its launch, drawing significant interest from international professionals and potential partners in the medical field.